GlassScriptPhysician profile
Ahmed Altibi
NPI 1013496553
$13,826.76
in general payments reported to CMS, 2019-2025
9 companies · $695 in 2025
The $695 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2021: $2,119 · 2022: $129 · 2023: $816 · 2024: $9,940 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,861 · Food and Beverage: $3,346 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,861.01 |
| Food and Beverage | $3,346.15 |
| Education | $244.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $9,301.07 | 2022-2024 | Versacross Access Solution |
| Biotronik INC. | $2,199.61 | 2021-2022 | |
| Medtronic, INC. | $1,997.58 | 2024-2025 | Micra |
| Daiichi Sankyo INC. | $121.36 | 2024 | Injectafer |
| Gilead Sciences, INC. | $64.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.96 | 2019 | |
| Abbott Laboratories | $50.00 | 2024 | Ensite |
| Abiomed | $29.67 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Altibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.